Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Managing hematologic toxicities: novel therapies.

Anita Nirenberg1

  • 1Columbia University School of Nursing, 617 W 168th St, New York, NY 10032, USA.

Cancer Nursing
|March 18, 2004
PubMed
Summary

New hematopoietic growth factors like pegfilgrastim and darbepoetin alfa effectively manage chemotherapy side effects, reducing infection risk and improving patient quality of life.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Supporting the health of unaccompanied immigrant children in a humanitarian crisis: An American Academy of Nursing consensus paper.

Nursing outlook·2026
Same author

The Potential Role for Smartphones Among Older Adults with Chronic Noncancer Pain: A Qualitative Study.

Pain medicine (Malden, Mass.)·2017
Same author

Distress and Coping Self-Efficacy in Inpatient Oncology Nurses.

Oncology nursing forum·2016
Same author

Mobile health-based approaches for smoking cessation resources.

Oncology nursing forum·2013
Same author

Current practices in advance care planning: implications for oncology nurses.

Clinical journal of oncology nursing·2011
Same author

Oncology nurses' use of National Comprehensive Cancer Network clinical practice guidelines for chemotherapy-induced and febrile neutropenia.

Oncology nursing forum·2010

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Chemotherapy-induced myelosuppression (neutropenia and anemia) increases infection risk, fatigue, and reduces quality of life and survival.
  • Myelosuppression can necessitate chemotherapy dose reductions or delays, impacting treatment efficacy.
  • Hematopoietic growth factors are established supportive therapies for chemotherapy-associated neutropenia and anemia.

Purpose of the Study:

  • To evaluate the efficacy and safety of novel hematopoietic growth factor preparations in managing chemotherapy-induced myelosuppression.
  • To assess the potential of new treatments to improve patient outcomes and reduce treatment-related complications.

Main Methods:

  • Review of recently reported studies on pegfilgrastim and darbepoetin alfa.
  • Analysis of treatment outcomes in patients receiving these new growth factor preparations during chemotherapy.

Main Results:

  • Pegfilgrastim administration once per chemotherapy cycle safely and effectively treats patients at risk for neutropenia.
  • Weekly or biweekly darbepoetin alfa therapy manages anemia effectively in cancer patients.
  • These novel preparations demonstrate potential for significant improvements in treatment outcomes.

Conclusions:

  • New hematopoietic growth factors offer improved management of chemotherapy-induced neutropenia and anemia.
  • These treatments can reduce infection-related morbidity and mortality, decrease transfusion needs, and enhance patient quality of life.
  • Extended dosing intervals may lower healthcare costs and improve patient adherence to cancer therapy.

Related Experiment Videos